助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   转移乳腺癌 的翻译结果: 查询用时:0.017秒
图标索引 在分类学科中查询
所有学科
肿瘤学
外科学
更多类别查询

图标索引 历史查询
 

转移乳腺癌
相关语句
  metastatic breast cancer
     Results The positive rates of CA15 3(>30U/ml) and CEA(>15ng/ml) were lower in patients with benign and without metastatic breast cancer. The sensitivity in patients with metastatic and reoccurred breast cancer was 75% in CA15 3,33% in CEA. CA15 3 increased before the clinical diagnosis.
     结果 良性疾病和未转移乳腺癌患者的血清CA15 3( >30U/ml)和CEA( >15ng/ml)的阳性率较低 ,已有转移或复发的乳腺癌患者血清CA15 3的敏感性为 75 % ,CEA的敏感性为 33% ,CA15 3值升高要比临床诊断早。
短句来源
     Theexpression of CK19、CEAmRNA by RQ-PCR in peripheral blood samples from 28 normalhealthy volunteers,20 patients with benign breast disease and 108 patients with breastcancer(88 patients with operable breast cancer and 20 patients with metastatic breast cancer)were also tested.
     -actin 为内对照,测定乳腺癌细胞株MCF7 及19 例新鲜乳腺癌组织中特异性mRNA 表达情况,以及测定28 例健康女性志愿者、20 例良性乳腺疾病患者、108 例乳腺癌患者(88 例可行手术切除乳腺癌患者、20 例复发转移乳腺癌患者)的外周血中CK19、CEAmRNA 的表达。
短句来源
     The positive rate of HER-2 ECD in sera of healthy subjects was no difference to that of breast cancer patients(P>0.05), but significant differenceto that of metastatic breast cancer patients (P<0.01).
     健康人群(20名)与乳腺癌患者(140例)血清HER-2ECD阳性率之间的差异无统计学意义(P>0·05),但与转移乳腺癌患者(10例)血清HER-2ECD阳性率之间差异有统计学意义(P<0·01)。
短句来源
     Relapsed and metastatic breast cancer(report of 34 cases)
     复发转移乳腺癌(附34例报告)
短句来源
     Methods 34 patients with recurrent and metastatic breast cancer were treated with Navelbine in this clinical study,and 16 patients were treated by the NP(DDP+NVB)regimen,12 patients by the NA(ADM+NVB)regimen,6 patient by single-agent NVB.34 patients received above regimens for two cycles(3~4 week a cycle).
     方法34例复发转移乳腺癌选用NP(NVB+DDP)治疗16例,NA(NVB+ADM)方案治疗12例,NVB单药治疗6例。 均3~4周为一周期,连用2周期以上,评价疗效及不良反应。
短句来源
更多       
  “转移乳腺癌”译为未确定词的双语例句
     The expression of PTEN protein was markedly lower in breast carcinomas with lymph node metastasis than in those without(32.1% vs 61.8% P<0.05).
     伴有淋巴结转移的乳腺癌中PTEN蛋白阳性表达率(32.1%)显著低于无淋巴结转移乳腺癌(61.8%),P<0.05;
短句来源
     The positive rates of MCP-1mRNA,MIP-1αmRNA were significantly lower in the cases of histologic grade Ⅰ+Ⅱ,maxial diameter of mass ≤2cm and without-metastasis of lymphnode than that in the ones of histological grade Ⅲ, maxial diameter of mass >2cm and with-metastasis of lymphnode in the breast cancer (P<0.05 or P<0.01)。
     组织学分级Ⅰ+Ⅱ级、肿块最大径≤2cm和区域淋巴结未转移乳腺癌MCP-1mRNA,MIP-1αmRNA表达阳性率明显低于组织分级Ⅲ级、肿块最大径>2cm和区域淋巴结转移病例,均有显著或高度显著差异(P<0.05或P<0.01)。
短句来源
     The positive rates of PTENmRNA were significantly higher in the cases of ER(+), histological gradeⅠ+Ⅱ, the maxial diameter of mass ≤2cm and without-metastasis of lymphnode than that in the ones of ER(-), histological grade Ⅲ, the maxial diameter of mass >2cm and with-metastasis of lymphnode in breast cancer, but those of P73mRNA were opposite.
     ER(+)、组织学分级Ⅰ+Ⅱ级、肿块最大径≤2cm和淋巴结未转移乳腺癌病例PTENmRNA表达阳性率明显高于ER(-)、组织学分级Ⅲ级、肿块最大径>2cm和淋巴结转移病例,但P73mRNA则相反;
短句来源
     Ⅲ~Ⅳ stages of breast cancer showed strong expressions of CD44V6 than Ⅰ~Ⅱ stages of breast cancer, and CD44V6 expression in lymph node metastasis was obviously higher than that in non lymph node metastasis.
     CD44V6在Ⅲ~Ⅳ期乳腺癌中表达明显高于Ⅰ~Ⅱ期 ,有淋巴结转移乳腺癌组织中CD44V6表达显著高于无淋巴结转移者 ;
短句来源
     3. CD4 +/CDS + value in patients with breast cancer plays an auxiliary role in prognostic evaluation when combined with metastatic status of axillary lymph nodes.
     (3)乳腺癌患者CD_3~+/CD_8~+比值可辅助评估伴腋淋巴转移乳腺癌患者的预后.
短句来源
更多       
  相似匹配句对
     Intraskeletal Myofiber Metastasis of Breast Carcinoma
     乳腺癌的横纹肌纤维内转移
短句来源
     The clinical course of bone metastases of breast cancer
     乳腺癌转移的临床病程
短句来源
     Chemoprevention of breast cancer
     乳腺癌的药物预防
短句来源
查询“转移乳腺癌”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  metastatic breast cancer
An 86-year-old woman with a history of metastatic breast cancer developed two episodes of streptococcal bacteraemia and erysipelas separated by an interval of 3 months.
      
P-gp expression and response to chemotherapy were comparatively investigated in 19 patients with metastatic breast cancer.
      
In spite of significant recent advances, cure after a diagnosis of metastatic breast cancer is a rather elusive goal utilizing current therapeutic options.
      
The role of taxanes has been expanded, and new data have started to demonstrate their improved efficacy, compared to older agents, as first-line or second-line therapy for patients with metastatic breast cancer who are eligible for systemic therapy.
      
The social and economic importance of metastatic breast cancer in our society makes this a priority.
      
更多          


From September to November 1985, Ca 15-3 kits (Centocor U.S.) were used for RIA in patients with or without breast diseases including 46 cases of malignant tumor, 20 cases of benign lesion, 48 healtty women and 1,044 women with high risk factors. The positive rate of Ca 15-3 was 100%(4/4) in advanced breast cancer;33.3% (13/39) in operable breast cancers 35.7%(5/14) in breast cancer with axillary metastases; 15%(3/20) in benign lesions and 11.9% (124/1044) in women with high risk factors. Major interest is focused...

From September to November 1985, Ca 15-3 kits (Centocor U.S.) were used for RIA in patients with or without breast diseases including 46 cases of malignant tumor, 20 cases of benign lesion, 48 healtty women and 1,044 women with high risk factors. The positive rate of Ca 15-3 was 100%(4/4) in advanced breast cancer;33.3% (13/39) in operable breast cancers 35.7%(5/14) in breast cancer with axillary metastases; 15%(3/20) in benign lesions and 11.9% (124/1044) in women with high risk factors. Major interest is focused in women with high risk factors for breast cancer in this series. They are being followed clinically and with RIA of Ca 15-3 as well.

1985年9~11月,我们使用美国Centocor公司提供的乳腺癌单克隆抗体Ca15-3诊断盒,测定乳腺恶性肿瘤46例,良性病变20例,健康妇女48人以及乳腺癌易患人群1,044例。结果,晚期乳腺癌阳性率为100%(4/4);可手术乳腺癌33.3%(13/39);伴腋淋巴结转移的乳腺癌35.7%(5/14);良性病变15%(3/20);乳腺癌易患人群11.9%(124/1,044)。对乳腺癌易患人群的测定,仅仅是一次尝试,我们将进一步复查和跟踪那些高于正常的妇女。

Aminoglutethimide was given po 250 mg qid and hydrocortisone po 50 mg bid for more than 1 month (29 courses in 27 oatients). The estrogen receptors (ER) were measured by 3H estradiol binding method. The overall objective response rates(complete and partial remissions)in ER positive and negative groups were 7/15 and 0/14, respectively (p<0.05). In respect of the locations the response rates were: soft tissue 5/9, bone 4/10, and viscera 0/4. The response rate in first relapse of me'tastatic cancer(4/4) seemed...

Aminoglutethimide was given po 250 mg qid and hydrocortisone po 50 mg bid for more than 1 month (29 courses in 27 oatients). The estrogen receptors (ER) were measured by 3H estradiol binding method. The overall objective response rates(complete and partial remissions)in ER positive and negative groups were 7/15 and 0/14, respectively (p<0.05). In respect of the locations the response rates were: soft tissue 5/9, bone 4/10, and viscera 0/4. The response rate in first relapse of me'tastatic cancer(4/4) seemed to be slightly higher (p>0.05) than that in recur-rences(3/11).The adverse reactions were mild.The value of ER determination in therapy of breast cancer is emphasized.

氨格鲁米特治疗不同ER状态的复发转移乳腺癌29例次,口服剂量为0.25g,qid。持续用药1mo以上。结果表明对ER阳性乳腺癌的有效率为7/15(47%),ER阴性为0/14(p<0.05)。ER阳性乳腺癌中以首次复发转移的病人,骨及软组织病灶的效果相对较好。其副反应不严重,极少需要停药,多可自行消失。临床应用时应通过ER检查,提高治疗的合理性。

In this study,twenty- seven in infiltrating ductal carcinomas of breast

本研究应用层粘连蛋白(LN)抗体,对27例乳腺癌、5例乳腺良性病变进行了免疫组织化学研究。结果发现乳腺良性病变时,LN以均匀完整的线型阳性反应显示在乳腺导管及小叶基膜处。乳腺癌时,LN的染色表现为癌细胞胞浆内弥漫状阳性反应。27例乳腺癌中,癌细胞LN染色强度不同,伴有转移的乳腺癌LN染色多数较强,强度在++~的为7/12(58.3%);不伴有转移的病例,LN染色多数较浅或为阴性,强度在++~+++的病例为3/15(20%)。说明癌细胞内源性LN染色强弱与肿瘤转移密切相关,内源性LN的合成可能改变肿瘤细胞的浸润活性。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关转移乳腺癌的内容
在知识搜索中查有关转移乳腺癌的内容
在数字搜索中查有关转移乳腺癌的内容
在概念知识元中查有关转移乳腺癌的内容
在学术趋势中查有关转移乳腺癌的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社